Orthocell (ASX:OCC) share price surges 13% on study success

Shares in the medical company are surging today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success.

At the time of writing, the Orthocell share price is trading hands at 58 cents, up 12.62%.

Orthocell is developing new medical devices and cellular therapies to help people recover from injury.

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

Why is the share price surging?

It appears investors are responding to positive results from a clinical trial into the use of one of Orthocell's lead products, OrthoATI.

In today's release, Orthocell said its data confirmed this product could safely reduce pain in patients suffering from rotator cuff tears. OrthoATI is more effective than steroid injections for treating this injury, according to the company.

Orthocell now plans to speed up its commercialisation plans for OrthoATI in the United States, including conducting a study in front of the Food and Drug Administration.

Orthocell told the market today it believed it could use its OrthoATI treatment to help 480,000 patients per year in the US alone. The company sees this as a US$4 to $5 billion market opportunity (AU $5.6 to $7 billion).

Management commentary

Orthocell managing director Paul Anderson welcomed the news, saying it was an important milestone. He added:

We are absolutely delighted with the study results for this challenging and debilitating condition which clearly demonstrates that OrthoATI is more effective than steroid injection for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.

We are now in a very strong position to progress our US commercialisation strategy to deliver the first injectable cell therapy in orthopaedics that truly addresses the cause of degeneration and returns patients to full use of their chronically damaged tendons.

Orthocell share price snapshot

The Orthocell share price has lifted more than 38% in the past 12 months and is up 27.78% this year to date.

In contrast, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 11% in the past year.

Shares in the company reached a 52-week high of 66 cents, while the low was 40.5 cents.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Why are Telix Pharmaceuticals shares on the slide today?

Big merger news isn't exciting investors just yet.

Read more »

two hands wearing medical gloves make the shape of a heart, indicating the best healthcare shares on the ASX market
Healthcare Shares

Down more than 18% in a month with a 7% yield, are Sonic Healthcare shares too cheap to ignore?

This could be a very healthy opportunity to buy.

Read more »

A man in a business suit jumps over a hurdle with a blue sky background.
Healthcare Shares

Why brokers think CSL shares could be on track for $200

CSL needs to tick a lot of boxes, before it can clear the $200 hurdle.

Read more »